NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form. Performance Measure Name: Venous Thromboembolism Prophylaxis

Similar documents
NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

HOSPITAL OUTPATIENT DEPARTMENT QUALITY MEASURES Stroke OP STROKE GENERAL DATA ELEMENT LIST

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only

NQF ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: The Joint Commission Only CMS Voluntary Only

AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS

Prevention of Venous Thromboembolism in Department of Veterans Affairs Hospitals

Risk of venous thromboembolism and benefits of prophylaxis use in hospitalized medically ill US patients up to 180 days post-hospital discharge

A Prospective, Controlled Trial of a Pharmacy- Driven Alert System to Increase Thromboprophylaxis rates in Medical Inpatients

ORIGINAL RESEARCH. BACKGROUND: The clinical venous thromboembolism (VTE) burden remains high in the United States, despite guidelines

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN

Venous thromboembolism (VTE), which includes

ASMBS POSITION STATEMENT ON PROPHYLACTIC MEASURES TO REDUCE THE RISK OF VENOUS THROMBOEMBOLISM IN BARIATRIC SURGERY PATIENTS

Lack of Clinical Benefit of Thromboprophylaxis in Patients Hospitalized in a Medical Unit Over a 10-year Span

EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States. Findings From the Nationwide Inpatient Sample

Thromboprophylaxis rates in US medical centers: success or failure?

BACKGROUND AND OBJECTIVE: Hospital-acquired venous thromboembolic events

Monitoring of Thromboembolic Events Prophylaxis: Where Do We Stand?

Boston Experience: Benchmark for the Nation

Boston Experience: Benchmark for the Nation

Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project

Improved Use of Thromboprophylaxis for Deep Vein Thrombosis Following an Educational Intervention

Ovid: A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Me... Page 1 of 18

Measure Information Form

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

Section 1 Rationale for VTE Prophylaxis January

Performance Measure Name: Tobacco Use: Assessing Status after Discharge

SCORES FOR 4 TH QUARTER, RD QUARTER, 2014

Venous thromboembolism risk assessment in hospitalised patients: A new proposal

Results from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY

Prevention of thromboembolic events in surgical patients through the creation and implementation of a computerized risk assessment program

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

General. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations

1. SCOPE of GUIDELINE:

Venous thromboembolism (VTE) is a leading

venous thromboembolism

Dr Fahad Al-Hameed MD, FCCP, FRCPC Consultant Intensivist & Pulmonologist Professor Asst. of Medicine/Critical Care KSAU-HS Deputy chairman,

Getting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis

Venous Thromboembolism (VTE): Prophylaxis and the Incidence of Hospital Acquired VTE(HAQ VTE) Olaide Akande, MBChB Mentor: John Hall, MD, FACP

Prevalence of Deep Vein Thrombosis and Associated Factors in Adult Medical Patients Admitted to the University Teaching Hospital, Lusaka, Zambia

External validity of placebo-controlled trials of thromboprophylaxis for medical patients cited in clinical practice guidelines

DATA FROM THE POPULAtion-based

Σάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία» Αναγνώριση παραγόντων κινδύνου της φλεβικής θρόμβωσης.

Medical Patients: A Population at Risk

SUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS

VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT

Measure Information Form

SOC s Guide to the 2013 CMS New Core Measures for Stroke

The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis.

Appendix G Explanation/Clarification Summary

OP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.

Accepted for publication in the Journal of Thrombosis and Haemostasis doi: /j x

Venous Thromboembolism Prevention Guidelines for Medical Inpatients: Mind the (Implementation) Gap

Prevention of Venous Thromboembolism

Performance Measure Name: TOB-3 Tobacco Use Treatment Provided or Offered at Discharge TOB-3a Tobacco Use Treatment at Discharge

Venous Thromboembolism Risk and Prophylaxis in Hospitalized Patients in Iraq

What evidence exists that describes the efficacy of mechanical prophylaxis for venous thromboembolism (VTE) in adult surgical patients?

Venous Thromboembolism Prophylaxis for Medical Service Mostly Cancer Patients at Hospital Discharge

Is There a Role for Prophylaxis in Cancer Patients During Therapy?

Pradaxa (dabigatran)

ORIGINAL ARTICLE VASCULAR. Xiaohan Liu a,, Chengyuan Liu a,, Xi Chen a, Wenwen Wu b and Gendi Lu a, * Abstract INTRODUCTION

A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method

Prophylaxis for Thromboembolism in Hospitalized Medical Patients

Improving Hospital Venous Thromboembolism Prophylaxis With Electronic Decision Support

Drug Class Monograph

Venous Thromboembolism National Hospital Inpatient Quality Measures

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form

VTE in the Trauma Population

SUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14, 09/15/15,09/21/17. THROMBOEMBOLISM PROPHYLAXIS

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

Understanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal

Anticoagulation for prevention of venous thromboembolism

Clinical Safety & Effectiveness Session # 9

Optimizing Prevention of Hospital-acquired Venous Thromboembolism (VTE): Prospective Validation of a VTE Risk Assessment Model

Deep Vein Thrombosis among Intensive Care Unit Patients; an Epidemiologic Study

Using Clinical Vignettes to Evaluate VTE Protocol Adherence

Is Development of Postoperative Venous Thromboembolism Related to. Thromboprophylaxis Use? A Case-Control Study in the Veterans Health Administration

Venous Thromboembolism. Prevention

Venous Thromboembolism in Heart Failure: Preventable Deaths During and After Hospitalization

The Flowtron Active Compression System Tri Pulse TM Garment and ACS800 Pump

Top Ten Reasons For Failure To Prevent Postoperative Thrombosis

Xarelto (rivaroxaban)

NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE

SUBSTANCE USE (SUB) NATIONAL HOSPITAL INPATIENT QUALITY MEASURES. Collected For: The Joint Commission Only

Title: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)

Cover Page. The handle holds various files of this Leiden University dissertation

Prophylaxis for Venous Thromboembolism Following Total Knee Arthroplasty: A Survey of Korean Knee Surgeons

Prophylaxis against venous thromboembolism in hospitalized medical patients: an evidence based and practical approach

VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies

Venous Thrombosis in Asia

Oral Anticoagulation Drug Class Prior Authorization Protocol

FINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY

RESEARCH. Venous thromboprophylaxis in UK medical inpatients

Prevention of Venous Thromboembolism in High-Risk Patients

Bristol-Myers Squibb/Pfizer Alliance Independent Medical Education

Results from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine

THE CHALLENGES OF COMPLIANCE WITH VTE PROPHYLAXIS GUIDELINES. Pr I. ELALAMY Service d Hématologie Biologique HOPITAL TENON ER2 UPMC PARIS

David Rosenberg, MD, MPH; Ann Eichorn, MS; Mauricio Alarcon; Lauren McCullagh, MPH; Thomas McGinn, MD, MPH; Alex C.

Transcription:

Last Updated: Version 4.3 NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Measure Set: Venous Thromboembolism (VTE) Set Measure Set I #: Performance Measure Name: Venous Thromboembolism Prophylaxis escription: This measure assesses the number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery end date for surgeries that start the day of or the day after hospital admission. Rationale: Hospitalized patients at high-risk for VTE may develop an asymptomatic deep vein thrombosis (VT), and die from pulmonary embolism (PE) even before the diagnosis is suspected. The majority of fatal events occur as sudden or abrupt death, underscoring the importance of prevention as the most critical action step for reducing death from PE (Heit, 2008). The estimated annual incidence of deep-vein thrombosis (VT) and pulmonary embolism (PE), known collectively as venous thromboembolism (VTE), is approximately 900,000 (Heit, 2008). Approximately two-thirds of cases of VT or PE are associated with recent hospitalization. This is consistent with the 2001 report by The Agency for Healthcare Research and Quality (AHRQ). AHRQ indicates that the appropriate application of effective preventive measures in hospitals has major potential for improving patient safety by reducing the incidence of venous thromboembolism (Shojania, 2001). espite its proven effectiveness, rates of appropriate thromboprophylaxis remain low in both medical and surgical patients. A recent analysis from the ENORSE survey, which evaluated prophylaxis rates in 17,084 major surgery patients, found that more than one third of patients at risk for VTE (38%) did not receive prophylaxis and that rates varied by surgery type (Cohen, et al., 2008). In a review of evidence-based patient safety practices, the Agency for Healthcare Research and Quality defined thromboprophylaxis against VTE as the "number one patient safety practice" for hospitalized patients (Shojania, 2001). Updated safe practices published by the National Quality Forum (NQF) recommend routine evaluation of hospitalized patients for risk of VTE and use of appropriate prophylaxis (National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism, 2006). -1

As noted by the ACCP, a vast number of randomized clinical trials provide irrefutable evidence that thromboprophylaxis reduces VTE events, and there are studies that have also shown that fatal PE is prevented by thromboprophylaxis (Geerts, et al. 2008). Type of Measure: Process Improvement Noted As: An increase in the rate Numerator Statement: Patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given: the day of or the day after hospital admission the day of or the day after surgery end date for surgeries that start the day of or the day after hospital admission Included Populations: Not Applicable Excluded Populations: None ata Elements: Reason for No VTE Prophylaxis Hospital Admission Reason for Oral Factor a Inhibitor Surgery End ate Surgical Procedure VTE Prophylaxis VTE Prophylaxis ate enominator Statement: All patients Included Populations: Not Applicable Excluded Populations: Patients less than 18 years of age Patients who have a length of stay (LOS) less than two days and greater than 120 days Patients with Comfort Measures Only documented on day of or day after hospital arrival Patients enrolled in clinical trials Patients who are direct admits to intensive care unit (ICU), or transferred to ICU the day of or the day after hospital admission with ICU LOS greater than or equal to one day Patients with IC-9-CM Principal iagnosis Code of Mental isorders or Stroke as defined in Appendix A, Table 7.01, 8.1 or 8.2 Patients with IC-9-CM Principal or Other iagnosis Codes of Obstetrics or VTE as defined in Appendix A, Table 7.02, 7.03 or 7.04-2

Patients with IC-9-CM Principal Procedure Code of Surgical Care Improvement Project (SCIP) VTE selected surgeries as defined in Appendix A, Tables 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, 5.24 ata Elements: Admission ate irthdate Clinical Trial Comfort Measures Only ischarge ate IC-9-CM Other iagnosis Codes IC-9-CM Principal iagnosis Code IC-9-CM Principal Procedure Code ICU Admission or Transfer ate ICU Admission or Transfer ICU ischarge ate Risk Adjustment: No ata Collection Approach: Retrospective data sources for required data elements include administrative data and medical record documents. Some hospitals may prefer to gather data concurrently by identifying patients in the population of interest. This approach provides opportunities for improvement at the point of care/service. However, complete documentation includes the principal or other IC-9-CM diagnosis and procedure codes, which require retrospective data entry. ata Accuracy: Variation may exist in the assignment of IC-9-CM codes; therefore, coding practices may require evaluation to ensure consistency. Measure Analysis Suggestions: In order to identify areas for improvement, hospitals may want to review the results based on specific IC-9-CM codes or patient populations. ata could then be analyzed to determine additional information about the type(s) of prophylaxis that were administered or evaluate documentation regarding nonuse of prophylaxis for similar patient groups. Sampling: Yes, please refer to the measure set specific sampling requirements and for additional information see the Population and Sampling Specifications. ata Reported as: Aggregate rate generated from count data reported as a proportion. Selected References: Amin A, Spyropoulos AC, obesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010; 29:326-339. Caprini JA, Arcelus JI. State of the art venous thromboembolism prophylaxis. SCOPE on Phlebology & Lymphology 1:2005, 228-240. -3

Cohen AT, Tapson VF, ergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENORSE study): a multinational cross-sectional study. Lancet. 2008;371:387-394. Geerts WH, ergqvist, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism. The Eighth ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2008; 133:381S-453S. Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. r J Surg. 1996 Oct;83(10):1394. Goldhaber SZ, Tapson VF; VT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound confirmed deep vein thrombosis. Am J Cardiol. 2004; 93:259-262. Guyatt, G.H., Akl, E.A., Crowther, M., Gutterman,., Schunemann, H. Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-ased Clinical Practice Guidelines. CHEST 2012; 141(2)(Supp):7S-47S. Heit JA, Cohen AT, Anderson FA Jr, et al., Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US, lood (ASH Annual Meeting Abstracts), 2005;106:Abstract 910. Heit JA, Silverstein M, Mohr N, Petterson TM, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000: 160:809-15. Hyers TM. Management of venous thromboembolism. Arch Intern Med. 2003;163:759-768. Kakkar AK, Cohen AT, Tapson VF, et al; ENORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENORSE survey): findings in surgical patients. Ann Surg. 2010;251:330-338. Kirwan CC, Nath E, yrne GJ, McCollum CN. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. MJ 2003;327:597-8. Kucher N, Koo S, Quiroz R, Cooper JM, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. New England Journal of Medicine. 2005, 352(10), 969-1036. Michota FA. Venous thromboembolism prophylaxis in medical patients. Curr Opin Cardiol. 2004 Nov;19(6):570-4. National Quality Forum. National Voluntary Consensus Standards for Prevention and Care of Venous Thromboembolism: Policy, Preferred Practices, and Initial Performance Measures. A Consensus Report. Washington, C. NQF; 2006. Schleyer AM, Schreuder A, Jarman KM, et al. Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States. Am J Med Qual. 2011; 26:174-80. Shojania KG, uncan W, Mconald M, et al. (Eds.). (2001). Making healthcare safer; A critical analysis of patient safety practices (Evidence Report/Technology Assessment No. 43). Prepared by the University of California at San Francisco-Stanford Evidenced-based Practice Center under Contract no. 290-97-0013 (AHRQ Publication NO.01-E058). Rockville, M:Agency for Healthcare Research and Quality. -4

Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005;165:1458-1464. Tooher R, Middleton P, Pham C, Fitridge R, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg 2005; 241:397-415. Wittkowsky AK. Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am J Manag Care. 2004;10:S297-S306. -5

: Venous Thromboembolism Prophylaxis Numerator: Patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given: the day of or the day after hospital admission the day of or the day after surgery end date for surgeries that start the day of or the day after hospital admission enominator: All patients Start Variable Key: Length of Stay Initial ICU ay ICU LOS Initial Prophylaxis ay Initial Surgical Prophylaxis ay Run cases that are included in the VTE Initial Patient Population and pass the edits defined in the Transmission ata Processing Flow: Clinical through this measure. Length of Stay (in days) = ischarge ate Admission ate Length of Stay < 2 days >= 2 days IC-9-CM Principal iagnosis Code On Table 7.01 or 8.1 or 8.2 Not on Table 7.01 or 8.1 or 8.2 IC-9-CM Principal or Other iagnosis Code At least one on Table 7.02 or 7.03 or 7.04 None on Table 7.02 or 7.03 or 7.04 IC-9-CM Principal Procedure Code On Tables 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, 5.24 or Not on Tables 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, 5.24 H -6

H Comfort Measures Only = 1 = 2, 3, 4 Clinical Trial = Y = N ICU Admission or = 2, 3 Transfer = 1 ICU Admission or Transfer ate = UT Non-UT Value Initial ICU ay (in days) = ICU Admission or Transfer ate Admission ate < 0 days Initial ICU ay = 0 days OR = 1 day ICU ischarge ate =UT Non-UT Value ICU LOS = ICU ischarge ate - ICU Admission or Transfer ate 2 days < 0 days ICU LOS >= 1 day = 0 days I -7

I VTE Prophylaxis Only = A or Only = 9 Reason for No VTE Prophylaxis Hospital Admission = N = Y Any = 1, 2, 3, 4, 5, 6, 7 or 8 E VTE Prophylaxis Only = 8 or = 8 and 9 Reason for Oral Factor a Inhibitor = N Any = 1, 2, 3, 4, 5, 6 or 7 = Y VTE Prophylaxis ate = UT Non-UT Value Initial Prophylaxis ay (in days) = VTE Prophylaxis ate Admission ate < 0 days Initial Prophylaxis ay = 0 days OR = 1 day E >= 2 days Surgical Procedure = N = Y J -8

J Surgery End ate = UT Non-UT Value Initial Surgical Prophylaxis ay (in days) = VTE Prophylaxis ate Surgery End ate < 0 days Initial Surgical Prophylaxis ay >= 2 days = 0 days OR = 1 day E Will e Rejected Case E In Numerator Population In Measure Population Not In Measure Population Stop -9

: Venous Thromboembolism Prophylaxis Numerator: enominator: Variable Key: Patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given: the day of or the day after hospital admission the day of or the day after surgery end date for surgeries that start the day of or the day after hospital admission All patients Length of Stay, Initial ICU ay, ICU LOS, Initial Prophylaxis ay, Initial Surgical Prophylaxis ay 1. Start processing. Run cases that are included in the VTE Initial Patient Population and pass the edits defined in the Transmission ata Processing Flow: Clinical through this measure. 2. Calculate Length of Stay. Length of Stay, in days, is equal to the ischarge ate minus the Admission ate. 3. Check Length of Stay a. If Length of Stay is less than 2 days, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. b. If Length of Stay is greater than or equal to 2 days, continue processing and proceed to IC-9-CM Principal iagnosis Code. 4. Check IC-9-CM Principal iagnosis Code a. If the IC-9-CM Principal iagnosis Code is on Table 7.01, 8.1, or 8.2, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. b. If the IC-9-CM Principal iagnosis Code is not on Table 7.01, 8.1, or 8.2, continue processing and proceed to IC-9-CM Principal or Other iagnosis Code. 5. Check IC-9-CM Principal or Other iagnosis Code a. If at least one of the IC-9-CM Principal or Other iagnosis Code is on Table 7.02, 7.03, or 7.04, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. b. If none of the IC-9-CM Principal or Other iagnosis Code is on Table 7.02, 7.03, or 7.04, continue processing and proceed to IC-9-CM Principal Procedure Code. 6. Check IC-9-CM Principal Procedure Code -10

a. If the IC-9-CM Principal Procedure Code is on Table 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, or 5.24, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. b. If the IC-9-CM Principal Procedure Code is missing or not on Table 5.17, 5.19, 5.20, 5.21, 5.22, 5.23, or 5.24, continue processing and proceed to Comfort Measures Only. 7. Check Comfort Measures Only a. If Comfort Measures Only is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If Comfort Measures Only equals 1, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. c. If Comfort Measures Only equals 2, 3, or 4, continue processing and proceed to Clinical Trial. 8. Check Clinical Trial a. If Clinical Trial is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If Clinical Trial equals Yes, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. c. If Clinical Trial equals No, continue processing and proceed to ICU Admission or Transfer. 9. Check ICU Admission or Transfer a. If ICU Admission or Transfer is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If ICU Admission or Transfer is equal to 2 or 3, continue processing and proceed to step 16 and check VTE Prophylaxis. c. If ICU Admission or Transfer is equal to 1, continue processing and proceed to ICU Admission or Transfer ate. 10. Check ICU Admission or Transfer ate a. If ICU Admission or Transfer ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If ICU Admission or Transfer ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. c. If ICU Admission or Transfer ate equals a Non Unable to etermine Value, continue processing and proceed to the Initial ICU ay calculation. -11

11. Calculate Initial ICU ay. Initial ICU ay, in days, is equal to ICU Admission or Transfer ate minus Admission ate. 12. Check Initial ICU ay a. If the Initial ay is less than 0 days, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. b. If the Initial ay is equal to 0 days or 1 day, the case will proceed to ICU ischarge ate. c. If the Initial ay is greater than or equal to 2 days, continue processing and proceed to step 16 and check VTE Prophylaxis. 13. Check ICU ischarge ate a. If the ICU ischarge ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If the ICU ischarge ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. c. If the ICU ischarge ate equals a Non Unable to etermine Value, continue processing and proceed to the ICU LOS calculation. 14. Calculate ICU LOS. ICU LOS is equal to ICU ischarge ate minus ICU Admission or Transfer ate. 15. Check ICU LOS a. If ICU LOS is less than zero days, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If ICU LOS is greater than or equal to 1 day, the case will proceed to a Measure Category Assignment of and will not be in the Measure Population. Stop processing. c. If ICU LOS is equal to zero days, continue processing and proceed to VTE Prophylaxis. 16. Check VTE Prophylaxis a. If VTE Prophylaxis is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If VTE Prophylaxis is only equal to A or only equal to 9, continue processing and proceed to check Reason for No VTE Prophylaxis Hospital Admission. 1. If Reason for No VTE Prophylaxis - Hospital Admission is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. -12

2. If Reason for No VTE Prophylaxis Hospital Admission equals No, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. 3. If Reason for No VTE Prophylaxis - Hospital Admission equals Yes, the case will proceed to a Measure Category Assignment of E and will be in the Numerator Population. Stop processing. c. If any VTE Prophylaxis is equal to 1,2,3,4,5,6,7 or 8, continue processing and proceed to recheck VTE Prophylaxis. 17. Recheck VTE Prophylaxis a. If VTE Prophylaxis is only equal to 8 or equal to 8 and 9, continue processing and proceed to check Reason for Oral Factor a Inhibitor. 1. If Reason for Oral Factor a Inhibitor is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. 2. If Reason for Oral Factor a Inhibitor equals No, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. 3. If Reason for Oral Factor a Inhibitor equals Yes, the case will proceed to check VTE Prophylaxis ate. b. If any VTE Prophylaxis is equal to 1, 2, 3, 4, 5, 6 or 7, continue processing and proceed to check VTE Prophylaxis ate. 18. Check VTE Prophylaxis ate a. If the VTE Prophylaxis ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If the VTE Prophylaxis ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. c. If the VTE Prophylaxis ate equals a Non Unable to etermine Value, continue processing and proceed to the Initial Prophylaxis ay calculation. 19. Calculate Initial Prophylaxis ay. Initial Prophylaxis ay, in days, is equal to the VTE Prophylaxis ate minus the Admission ate. 20. Check Initial Prophylaxis ay a. If Initial Prophylaxis ay is less than zero days, the case will proceed to a Measure category Assignment of and will be rejected. Stop processing. b. If Initial Prophylaxis ay is equal to zero days or 1 day, the case will proceed to a Measure Category Assignment of E and will be in the Numerator Population. Stop processing. c. If Initial Prophylaxis ay is greater than or equal to 2 days, continue processing and proceed to Surgical Procedure. -13

21. Check Surgical Procedure a. If Surgical Procedure is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If Surgical Procedure equals No, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. c. If Surgical Procedure equals Yes, continue processing and proceed to Surgery End ate. 22. Check Surgery End ate a. If the Surgery End ate is missing, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. b. If the Surgery End ate equals Unable to etermine, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. c. If the Surgery End ate equals a Non Unable to etermine Value, continue processing and proceed to the Initial Surgical Prophylaxis ay calculation. 23. Calculate Initial Surgical Prophylaxis ay. Initial Surgical Prophylaxis ay, in days, is equal to the VTE Prophylaxis ate minus Surgery End ate. 24. Check Initial Surgical Prophylaxis ay a. If the Initial Surgical Prophylaxis ay is greater than or equal to 2 days, the case will proceed to a Measure Category Assignment of and will be in the Measure Population. Stop processing. b. If the Initial Surgical Prophylaxis ay is equal to zero days or 1 day, the case will proceed to a Measure Category Assignment of E and will be in the Numerator Population. Stop processing. c. If the Initial Surgical Prophylaxis ay is less than 0 days, the case will proceed to a Measure Category Assignment of and will be rejected. Stop processing. -14